1444827-69-3

Upstream product

• 1444827-58-0 5-p-nitrobenzoyl-2-((2,3,4,6-tetra-O-acetyl-α-D-mannopyranos-1-yl)amino)thiazole 
• 93221-21-7 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl isothiocyanate 
• 786593-67-7 N-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranos-1-yl)thiourea 
• 1444827-52-4 2-[(2,3,4,6-tetra-O-acetyl-α-D-mannopyranos-1-yl)amino]-4-dimethylamino-1,3-thiazabuta-1,3-diene 
• 572-10-1 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl chloride 

Relevant academic research and scientific papers

Thiazolylaminomannosides as potent antiadhesives of type 1 piliated escherichia coli isolated from crohn's disease patients

Adherent-invasive Escherichia coli (AIEC) have previously been shown to induce gut inflammation in patients with Crohn's disease (CD). We developed a set of mannosides to prevent AIEC attachment to the gut by blocking the FimH bacterial adhesin. The crystal structure of the FimH lectin domain in complex with a lead thiazolylaminomannoside highlighted the preferential position for pharmacomodulations. A small library of analogues showing nanomolar affinity for FimH was then developed. Notably, AIEC attachment to intestinal cells was efficiently prevented by the most active compound and at around 10000-fold and 100-fold lower concentrations than mannose and the potent FimH inhibitor heptylmannoside, respectively. An ex vivo assay performed on the colonic tissue of a transgenic mouse model of CD confirmed this antiadhesive potential. Given the key role of AIEC in the chronic intestinal inflammation of CD patients, these results suggest a potential antiadhesive treatment with the FimH inhibitors developed.